Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2023 Dec 6;14:1345777. doi: 10.3389/fimmu.2023.1345777

Corrigendum: MSC therapy ameliorates experimental gouty arthritis hinting an early COX-2 induction

Juan Pablo Medina 1,, Ismael Bermejo-Álvarez 1,, Sandra Pérez-Baos 1, Rosa Yáñez 2,3, María Fernández-García 2,3, Damián García-Olmo 4,5,6, Aránzazu Mediero 1, Gabriel Herrero-Beaumont 1,*, Raquel Largo 1
PMCID: PMC10731447  PMID: 38124755

In the published article, there was an error in the Funding statement. The funding statement was displayed as “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by Fondo Europeo de Desarrollo Regional (FEDER).” The correct statement is “This study was supported by research grants from the Instituto de Salud Carlos III (PIE15/00048; PI15/00770; PI18/00261; PI20/00349; PI22/00352), co-funded by the European Union.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES